CTRI/2018/05/013864CompletedPhase 2
Clinical trial on Hyperlipidemia (Kasrat-e-Shahmuddam) with UNIM-763
Central Council for Research in Unani Medicine1 site in 1 country60 target enrollmentStarted: January 4, 2008Last updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Reduction of Serum Cholesterol and Serum Triglycerides
Study Overview
Brief Summary
Hyperlipidemia is an increase in either plasma cholesterol, plasma triglycerides. Epidemiological study indicate that cholesterol level above 250 mg/100 ml. significantly raise the risk for coronary heart disease *CHD).
Recent clinical trials show that treatment of hyperlipidemia with allopathic drugs reduces the risk for coronary heart disease. Some of the Unani drugs have the capacity to regulate lipid abnormalities. If atherosclerosis can be prevented by regulating the abnormal lipid metabolism, we may be able to manage successfully one aspect of coronary heart disease.
Study Design
- Study Type
- Interventional
- Allocation
- Not Applicable
- Masking
- Participant and Investigator Blinded
Eligibility Criteria
- Ages
- 30.00 Year(s) to 65.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •1.Serum cholesterol: > 200 mg/dl 2.Serum Triglycerides: >150 mg / dl 3.LDL: > 115 mg/ dl 4.HDL: > 40 5.Patient should be willing to cooperate the study protocol 6.Patient should be give written informed consent 7.Patient should not have any other disease.
Exclusion Criteria
- •1.Un control diabetes mellitus 2.History of IHD 3.History of drug/alcohol abuse 4.Non cooperative patients.
Outcomes
Primary Outcomes
Reduction of Serum Cholesterol and Serum Triglycerides
Time Frame: Baseline, 1st month, 2nd month, 3rd month
Secondary Outcomes
- Safety with Pathological and biochemical tests(Before and after treatment)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Treatment of Hyperlipedemia with Unani formulatioCTRI/2018/05/013864Central Council for Research in Unani Medicine60
Not yet recruiting
Phase 2
Clinical effectiveness of Unani drugs in comparison to conventional drug in the treatment of dyslipidaemia (abnormal amount of fat in the blood)CTRI/2019/05/019066Central Research Institute of Unani Medicine60
Recruiting
Phase 1
A Phase 1 study to evaluate safety and tolerability of Anti-PCSK9 Product (ZRC-3306) administered subcutaneously in healthy adult human subjectsCTRI/2024/01/062126Zydus Lifesciences Ltd Formerly Cadila Healthcare Limited60
Completed
Not Applicable
Venthamarai chooranam & yoga for hyperlipidemiaCTRI/2023/06/05350430
Completed
Phase 3
Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering DrugsHIV InfectionNCT01543035Calmy Alexandra34